Racura Oncology (RAC) Q4 2025 TU earnings summary

Executive summary

• First patient safely treated with RC220 and RC220 plus doxorubicin in Phase 1 trial for advanced solid tumours, marking a major clinical milestone.

• Human ethics approval received post-quarter for Phase 1 RC220 trial at two Hong Kong hospitals.

• Clinical leadership strengthened with appointments of Dr Jose Iglesias as Chief Medical Officer and Dr Simon Fisher as Vice President of Medical.

• Termination of global license agreement with City of Hope, retaining full freedom to operate with bisantrene.

• CEO presented at Gold Coast Investment Showcase and selected to present at ESMO 2025 conference.

Financial highlights

• Cash and cash equivalents at 30 June 2025 totaled $13.67 million.

• Over 83% of quarterly spending ($3.11m) directed to R&D and drug manufacturing.

• Net cash used in operating activities for the quarter was $(3.49)m; year-to-date $(4.58)m.

• Early conversion of options raised $28k during the quarter.

• Interest received for the quarter was $348k.

Outlook and guidance

• Prudent cash management positions the company to fund all activities through calendar year 2026.

• Estimated 3.92 quarters of funding available based on current cash burn.